{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:51Z","timestamp":1786988031625,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ejca.2020.02.041","type":"journal-article","created":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T00:37:14Z","timestamp":1585355834000},"page":"211-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"130","author":[{"given":"Nicole A.","family":"Romanski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke B.","family":"Holmstroem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ellebaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.02.041_bib1","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s00262-018-2241-x","article-title":"Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies","volume":"67","author":"Dobry","year":"2018","journal-title":"Canc Immun"},{"key":"10.1016\/j.ejca.2020.02.041_bib2","first-page":"V05170365","article-title":"Immunterapi er kr\u00e6ftbehandling med en helt ny bivirkningsprofil","volume":"179","author":"Kondrup","year":"2017","journal-title":"Ugeskrift for L\u00e6ger"},{"key":"10.1016\/j.ejca.2020.02.041_bib3","series-title":"Chapter 11 toxicities in immune checkpoint inhibitors, immune checkpoint inhibitors in cancer","author":"Lee","year":"2018"},{"key":"10.1016\/j.ejca.2020.02.041_bib4","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.ejca.2020.02.041_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Canc"},{"key":"10.1016\/j.ejca.2020.02.041_bib7","author":"Rasmussen"},{"key":"10.1016\/j.ejca.2020.02.041_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2016.12.017","article-title":"The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials","volume":"74","author":"Donia","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.02.041_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 and antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.ejca.2020.02.041_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/ITT.S141577","article-title":"Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events","volume":"6","author":"Davies","year":"2017","journal-title":"ImmunoTargets Ther"},{"issue":"11","key":"10.1016\/j.ejca.2020.02.041_bib12","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.02.041_bib13","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Supplement 4","key":"10.1016\/j.ejca.2020.02.041_bib14","doi-asserted-by":"crossref","first-page":"i119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.02.041_bib15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management","volume":"41","author":"Huffman","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.02.041_bib16","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.02.041_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/CMR.0b013e32835c7e68","article-title":"Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma","volume":"23","author":"Bernardo","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2020.02.041_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-018-2590-6","article-title":"Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients-real-world data","volume":"75","author":"Polkowska","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2020.02.041_bib19","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.02.041_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-018-9921-7","article-title":"Liver damage related to immune checkpoint inhibitors","author":"Nishida","year":"2019","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.ejca.2020.02.041_bib21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3747\/co.25.4235","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a brief review","volume":"25","author":"Myers","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejca.2020.02.041_bib22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40259-016-0204-3","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors","volume":"30","author":"Day","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejca.2020.02.041_bib23","author":"Svane"},{"issue":"18","key":"10.1016\/j.ejca.2020.02.041_bib24","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-2569","article-title":"Molecular pathways: immune checkpoint Antibodies and their toxicities","volume":"22","author":"Cousin","year":"2016","journal-title":"Clin Canc Res"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2020.02.041_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2517","article-title":"Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325\/KEYNOTE-054 pembrolizumab versus placebo trial","volume":"37","author":"Eggermont","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.02.041_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/JIPO.JIPO_12_18","article-title":"The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients'outcomes","volume":"1","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Precis Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2020.02.041_bib27","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.02.041_bib28","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti\u2013cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.02.041_bib29","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","author":"Weber","year":"2008","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2020.02.041_bib30","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Canc Res"},{"issue":"5","key":"10.1016\/j.ejca.2020.02.041_bib31","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.3747\/co.25.4047","article-title":"Predictors of immunotherapy-induced immune-related adverse events","volume":"25","author":"Kartolo","year":"2018","journal-title":"Curr Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920301155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920301155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:27:52Z","timestamp":1760732872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920301155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":29,"alternative-id":["S0959804920301155"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.02.041","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.02.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}